|
IQVIA™ Real-World Insights Bibliography
| Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study |
| Author(s): Avraham Karasik (1), Stefanie Lanzinger (2,3), Elise Chia-Hui Tan (4), Daisuke Yabe (5,6,7 8), Dae Jung Kim (9), Wayne H-H Sheu (10), Cheli Melzer-Cohen (1), Reinhard W. Holl (2), Kyoung-Hwa Ha (9), Kamlesh Khunti (11), Francesco Zaccardi (11), Anuradhaa Subramanian (12), Krishnarajah Nirantharakumar (12,13,14), Thomas Nyström (15), Leo Niskanen (16), Majken Linnemann Jensen (17), Fabian Hoti (18), Riho Klement (19), Anouk Déruaz-Luyet (20), Moe H.Kyaw (21), Lisette Koeneman (22), Dorte Vistisen (23, 24) Bendix Carstensen (23), Sigrun Halvorsen (25), Gisle Langslet (26), Soulmaz Fazeli Farsani (20), Elisabetta Patorno (27), Júlio Núñez (28), EMPRISE Europe and Asia Study Group
|
| Affiliations(s): "1
Maccabi Institute for Research and Innovation Center, Tel Aviv University, Tel Aviv, Israel
2
Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany
3
German Centre for Diabetes Research (DZD), München-Neuherberg, Germany
4
Department of Health Service Administration, China Medical University, Taichung, Taiwan
5
Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan
6
Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan
7
Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan
8
Preemptive Food Research Center, Gifu University Institute for Advanced Study, Gifu, Japan
9
Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea
10
Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan
11
Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK
12
Institute of Applied Health Research, University of Birmingham, Birmingham, UK
13
Midlands Health Data Research UK, Birmingham, UK
14
DEMAND Hub, University of Birmingham, Birmingham, UK
15
Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sweden
16
Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital, Lahti Finland and University of Eastern Finland, Kuopio, Finland
17
IQVIA Solutions Denmark A/S, Copenhagen, Denmark
18
IQVIA, Espoo, Finland
19
IQVIA, Tartu, Estonia
20
Boehringer Ingelheim International GmbH, Ingelheim, Germany
21
Boehringer Ingelheim International GmbH, US
22
Lilly Deutschland GmbH, Bad Homburg, Germany
23
Steno Diabetes Center Copenhagen, Herlev, Denmark
24
Department of Public Health, University of Copenhagen, Copenhagen, Denmark
25
Department of Cardiology, Oslo University Hospital Ullevål, and University of Oslo, Oslo, Norway
26
Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway
27
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA
28
Department of Cardiology, Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, CIBER Cardiovascular, Valencia, Spain" |
Publication(s): "Diabetes & Metabolism. 2023 Jan; 101418; ISSN 1262-3636
Virtual Conference: American Diabetes Association, 25-29 June 2021 and EASD 27 September -01 October"
|
| Document Type(s): Article, |
| Countries: Denmark, Finland, Germany, Norway, Spain, Sweden, UK, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study,
2023 |
|
L:
A: |
English
Clinical setting: hospital, Clinical setting: Primary care, |
|
 |
| |
| |
| Hypercholesterolaemia control in Spain: The same situation with different regional realities
|
| Author(s): Juan Pedro-Botet, Núria Plana, José María Mostaza, Juan José Gómez-Doblas, María Rosa Fernández Olmo, Carlos Escobar Cervantes, José Luis Díaz-Díaz, Raquel Campuzano Ruiz, Pedro Valdivielso, Juan Cosín-Sales
|
| Affiliations(s): Unidad de Lípidos y Riesgo Vascular, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, España
|
Publication(s): Clinica e investigacion en arteriosclerosis: publicacion oficial de la Sociedad Espanola de Arteriosclerosis, S0214-9168(23)00027-X. 27 Apr. 2023, doi:10.1016/j.arteri.2023.04.001
|
| Document Type(s): Abstract, |
| Countries: Spain, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease,
2023 |
|
L:
A: |
Spanish
Clinical setting: Primary care, Public Health, Quality of life, Survey research, |
|
|
| |
| |
| Burden of Hospitalizations and Outpatient Visits Associated With Moderate and Severe Acute Graft-Versus-Host Disease in Finland and Sweden: A Real-World Data Analysis |
| Author(s): Lorenzo Sabatelli, PhD,1 Mikko Keränen, MD, PhD,2 Elisabet Viayna, PhD,3 Montserrat Roset, BSc Stats,3 Nuria Lara, MD, MSc,3 Daniel Thunström, MSc Pharm,1 Minja Pfeiffer, PhD,1 Malin Nicklasson, MSc Pharm,4 Maija Itälä-Remes, MD, PhD5
|
| Affiliations(s): "1Incyte Biosciences International Sàrl, Morges, Switzerland; 2Helsinki University Hospital, Helsinki, Finland; 3IQVIA Real World Solutions, Barcelona, Spain; 4Department of Hematology and Coagulation, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 5Turku University Hospital, Turku, Finland "
|
Publication(s): Supportive Care in Cancer
|
| Document Type(s): Article, |
| Countries: Finland, Spain, Sweden, Switzerland, |
C:
Y: |
Health economics, Transplant,
2022 |
|
L:
A: |
English
Clinical setting: hospital, Observational study, Population Based Study, |
|
|
| |
| |
| Nutritional status and use of health resources after the implementation of an enteral nutrition program by PEG probe for neurological patients with home hospitalization
|
| Author(s): Blanco Ramos B, Lopez Garcia B, Gómez Bellvert N.
|
| Affiliations(s): Hospital General Universitario de Elda (Alicante). Carretera Elda-Sax SN. 03600
|
Publication(s): Nutr Hosp
. 2022 Jun 24;39(3):489-498. doi: 10.20960/nh.03813.
|
| Document Type(s): Article, |
| Countries: Spain, |
| Click here for the abstract |
C:
Y: |
Neurological disorders, Nutritional Disorders,
2022 |
|
L:
A: |
Spanish
Clinical setting: hospital, Cost benefit, Observational study, Population Based Study, Quality of life, |
|
|
| |
| |
| Overview of the European post-authorisation study register post-authorization studies performed in Europe from September 2010 to December 2018 |
| Author(s): Janet Sultana 1 2, Salvatore Crisafulli 3, Mariana Almas 4, Ippazio Cosimo Antonazzo 5 6, Esme Baan 7, Claudia Bartolini 6, Maria Paola Bertuccio 3, Fedele Bonifazi 8 9, Annalisa Capuano 10 11, Antonella Didio 8 9, Vera Ehrenstein 12, Mariagrazia Felisi 8 13, Carmen Ferrajolo 10 11, Andrea Fontana 14, Remy Francisca 7, Annie Fourrier-Reglat 15, Joan Fortuny 16, Rosa Gini 6, Giulia Hyeraci 6, Christel Hoeve 7, Christos Kontogiorgis 17, Valentina Isgrò 18, Panagiotis-Nikolaos Lalagkas 17, Luca L'Abbate 18, Deborah Layton 19, Annalisa Landi 8 9, Silvia Narduzzi 19, Leonardo Roque Pereira 20, Georgios Poulentzas 17, Concetta Rafaniello 10 11, Giuseppe Roberto 6, Giulia Scondotto 3, Liberata Sportiello 10 11, Maddalena Toma 8 9, Massoud Toussi 19, Katia Verhamme 7, Elisabetta Volpe 8 9, Gianluca Trifirò 18, |
| Affiliations(s): Pharmacy Department, Mater Dei Hospital, Msida, Malta.
2Exeter College of Medicine and Health, Exeter, UK.
3Department of Medicine, University of Verona, Verona, Italy.
4Real World Solutions Department, IQVIA, Lisbon, Portugal.
5Research Centre on Public Health (CESP), University of Milan-Bicocca, Milan, Italy.
6Agenzia Regionale di Sanità della Toscana, Florence, Italy.
7Department of Medical Informatics, Erasmus Medical Centre, Rotterdam, The Netherlands.
8TEDDY European Network of Excellence for Paediatric Clinical Research, Pavia, Italy.
9Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus, Bari, Italy.
10Department of Experimental Medicine, University of Campania "Vanvitelli", Naples, Italy.
11Campania Regional Center of Pharmacovigilance and Pharmacoepidemiology, Naples, Italy.
12Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
13CVBF Consorzio per Valutazioni Biologiche e Farmacologiche, Pavia, Italy.
14Unit of Biostatistics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
15Univ. Bordeaux, INSERM, Bordeaux Population Health Research Center, Team of Pharmacoepidemiology, UMR 1219, Bordeaux, France.
16RTI Health Solutions, Barcelona, Spain.
17Democritus University of Thrace, Alexandroupolis, Greece.
18Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
19Data Science Hub, Real World Solutions, IQVIA, London, UK.
20Department of Datascience & Biostatistics, University Medical Center Utrecht, Utrecht, The Netherlands. |
Publication(s): Pharmacoepidemiol Drug Saf
. 2022 Jun;31(6):689-705. doi: 10.1002/pds.5413. Epub 2022 Feb 11.
|
| Document Type(s): Article, |
| Countries: Denmark, France, Italy, Netherlands, Portugal, Spain, UK, |
| Click here for the abstract |
C:
Y: |
Drug safety, Drug Utlization Study,
2022 |
|
L:
A: |
English
Database Study, Review, |
|
|
| |
| |
| Effectiveness and safety of empagliflozin in routine care in Europe and East Asia: results from
the empagliflozin comparative effectiveness and safety (EMPRISE) study
|
| Author(s): A. Karasik1
, S. Lanzinger2
, E. Chia-Hui Tan3
, D. Yabe4
, D. Jung Kim5
, W. H-H Sheu6
, C. MelzerCohen1
, R.W. Holl2
, K. Ha5
, T. Nyström7
, L. Niskanen8
, M. Linnemann Jensen9
, M.H. Kyaw10, J.
Núñez11, EMPRISE EU and East Asia Study Group; |
| Affiliations(s): Maccabi Research & Innovation Center, Tel Aviv University, Tel Aviv, Israel, 2
Inst. for
Epidemiology & Medical Biometry, Uni. of Ulm, Ulm, Germany, 3National Research Inst. of Chinese
Medicine, Taipei, Taiwan, 4Dept. of Diabetes and Endocrinology, Gifu University Graduate School of
Medicine, Gifu, Japan, 5Dept. of Endocrinology & Metabolism, Ajou Uni. School of Medicine,
Suwon, Republic of Korea, 6Taipei Veterans General Hospital, Taipei, Taiwan, 7Dept. of Clinical
Science & Education, Södersjukhuset, Karolinska Institutet, Solna, Sweden, 8Department of Medicine,
Päijät-Häme Central Hospital, Lahti, Finland, 9
IQVIA, Copenhagen, Denmark, 10Boehringer
Ingelheim Pharmaceutical Inc., Ridgefield, USA, 11Dept. of Cardiology, Hospital Clínico
Universitario de Valencia, Valencia, Spain |
Publication(s):
https://doi.org/10.2337/DB21-127-LB
Virtual EASD 2021, 57 Annual Meeting, 27 September - 10 October 2021
|
| Document Type(s): Abstract, |
| Countries: Finland, Germany, Israel, Japan, South Korea, Spain, Sweden, Taiwan, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes,
2021 |
|
L:
A: |
English
Database Study, Methodology, Population Based Study, |
|
|
| |
| |
| Empagliflozin use versus dipeptidyl peptidase 4 inhibitors reduces risk ofcardiovascular and renal disease among type 2 diabetes patients in routinecare in europe and israel: EMPRISE study results |
| Author(s): T Nystroem1;AKarasik2; J Nunez3; S Lanzinger4; C Melzer-Cohen2; R W Holl4;P Casajust5; E Toresson Grip6; M Carrasco7; J Foersch8; K Karlsdotter9;M Tuovinen10; R Klement11;MHKyaw12; L Niskanen |
| Affiliations(s): Karolinska Institutet,Department of Clinical Science and Education, Södersjukhuset, Solna, Sweden;2Tel Aviv University, Maccabi Research and Innovation Center, Tel Aviv, Israel;3University of Valencia, Department of Cardiology, Hospital Clínico Universitariode Valencia, INCLIVA, CIBER Cardiovascular, Valencia, Spain;4University of Ulm,Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm, Germany;5Trial FormSupport, Real-World Evidence, Barcelona, Spain;6Swedish Institute for HealthEconomics Quantify Research, Stockholm, Sweden;7Boehringer Ingelheim EspañaS.A., Barcelona, Spain;8Boehringer Ingelheim Pharma GmbH & Co. Kg, HP CountryMedical Affairs, Ingelheim Am Rhein, Germany;9Boehringer Ingelheim AB, Stock-holm, Sweden;10Boehringer Ingelheim KY, Secondment Boehringer Ingelheim UKHEOR Team, Helsinki, Finland;11IQVIA, Global Database Studies, Tartu, Estonia;12Boehringer Ingelheim Pharmaceutical Inc., Connecticut, United States of America;13University of Eastern Finland, Kuopio, Finland; |
Publication(s): European Journal of Heart Failure (2021)23(Suppl. S2) 2?322doi:10.1002/ejhf.2297
|
| Document Type(s): Abstract, Article, |
| Countries: Finland, Germany, Israel, Spain, Sweden, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes,
2021 |
|
L:
A: |
English
Database Study, Meta analysis, Methodology, Population Based Study, |
|
|
| |
| |
| The Burden Of Hpv In Head And Neck Cancers - Design Of The Broaden Study |
| Author(s): Gómez Ulloa D1, Morais E2, Fenoll R1, Kothari S3, Giuliano A4, Mirghani H5, Mehanna H6, Waterboer T7, Roberts C3, Varga S3, Tu Y3, Pérez G3, Saah A3, Alemany L8 |
| Affiliations(s): 1 IQVIA, Barcelona, Spain 2 MSD, CORE, Lyon, France 3 Merck & Co. Inc., Center for Observational and Real-world Evidence, Kenilworth, NJ, US 4 Moffitt Cancer Center and Research Institute, Center for Immunization and Infection Research in Cancer, Tampa, FL, US 5 HEGP, ORL, Paris, France 6 InHANSE, Head and Neck Surgery, Birmingham, UK 7 German Cancer Research Center (DKFZ), Infections and Cancer Epidemiology, Heidelberg, Germany 8 Catalan Institute of Oncology - IDIBELL, On behalf of Unit of Cancer and Infection in the Cancer Epidemiology Research Programme, Hospitalet Del Llobregat, Spain |
Publication(s): IPVC, Barcelona, Spain, 23-27 March 2020
|
| Document Type(s): Oral presentation, |
| Countries: China, France, Germany, Italy, Japan, Portugal, Spain, |
C:
Y: |
Infectious disease, Oncology,
2020 |
|
L:
A: |
English
Burden of illness, Observational study, Retrospective Field Study, |
|
|
| |
| |
| Clinical management of serious infections attributable to carbapenem-resistant Gram-negative pathogens in Spanish hospitals |
| Author(s): Ferrer R1, Calvo-Montes J2, Maseda E3, Salavert M4, Bou G5, Díaz-Regañón J6, López D6, Lozano V6, Gómez-Ulloa D7, Fenoll R7, Sánchez E7, McCann E8 |
| Affiliations(s): 1 Vall d'Hebron University Hospital, Barcelona, Spain 2 Marqués de Valdecilla University Hospital, Santander, Spain 3 La Paz University Hospital, Madrid, Spain 4 La Fe University and Polytechnic Hospital, Valencia, Spain 5 La Coruña University Hospital, La Coruña, Spain, Spain 6 Merck Sharp & Dohme Corp., Madrid, Spain 7 IQVIA, Barcelona, Spain 8 Merck & Co., Inc., Kenilworth, NJ, US |
Publication(s): ECCMID, Paris, France, 18-21 April 2020
|
| Document Type(s): Poster, |
| Countries: Spain, |
C:
Y: |
Infectious disease,
2020 |
|
L:
A: |
English
Observational study, Retrospective Field Study, |
|
|
| |
| |
| Resource utilisation associated with infections attributable to carbapenem-resistant Gram-negative pathogens in southern European hospitals |
| Author(s): Durante Mangoni E1, Georgopoulos D2, Fernández-Martínez M3, Mastroianni C4, Viale P5, Bassetti M6, Ferrer R7, Giamarellos-Bourboulis E8, Maseda E9, Salavert M10, Perivoliotis E11 ,Bou Arevalo G12, Koutsoukou A13, Mantzarlis K14, Lozano V15, Gómez-Ulloa D16, Roset M16, McCann E17 |
| Affiliations(s): 1 ‘L. Vanvitelli’ University, Monaldi Hospital, Naples, Italy 2 University Hospital of Crete, Crete, Greece 3 Marqués de Valdecilla University Hospital, Santander, Spain 4 Policlinico Umberto I, Rome, Italy 5 Policlinico S. Orsola-Malpighi, Bologna, Italy 6 University of Genova and Policlinico San Martino, Genova, Italy 7 Vall d'Hebron University Hospital, Barcelona, Spain 8 National and Kapodistrian University of Athens, Athens, Greece 9 University Hospital La Paz, Madrid, Spain 10 Hospital Universitario y Politécnico de La Fe, València, Spain 11 Evaggelismos General Hospital, Athens, Greece 12 Hospital Universitario La Coruña, La Coruña, Spain 13 National and Kapodistrian University and General Hospital for Chest Diseases 'I Sotiria’ , Athens, Greece 14 University Hospital of Larissa, Larisa, Greece 15 Merck Sharp & Dohme, Madrid, Spain 16 IQVIA, Barcelona, Spain 17 Merck & Co., Inc., Kenilworth, NJ, US |
Publication(s): ECCMID, Paris, France, 18-21 April 2020
|
| Document Type(s): Oral presentation, |
| Countries: Greece, Italy, Spain, |
C:
Y: |
Infectious disease,
2020 |
|
L:
A: |
English
Observational study, Retrospective Field Study, |
|
|
| |
| |
 1 of 38 
|
|
